

Product datasheet for **TL313733V**

Corticotropin Releasing Factor Receptor 2 (CRHR2) Human shRNA Lentiviral Particle (Locus ID 1395)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	Corticotropin Releasing Factor Receptor 2 (CRHR2) Human shRNA Lentiviral Particle (Locus ID 1395)
Locus ID:	1395
Synonyms:	CRF-RB; CRF2; CRFR2; HM-CRF
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	CRHR2 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml.
RefSeq:	NM_001202475 , NM_001202481 , NM_001202482 , NM_001202483 , NM_001883 , NM_001883.1 , NM_001883.2 , NM_001883.3 , NM_001883.4 , NM_001202483.1 , NM_001202481.1 , NM_001202482.1 , NM_001202475.1 , BC096830 , NM_001883.5
UniProt ID:	Q13324
Summary:	The protein encoded by this gene belongs to the G-protein coupled receptor 2 family, and the subfamily of corticotropin releasing hormone receptor. This receptor shows high affinity for corticotropin releasing hormone (CRH), and also binds CRH-related peptides such as urocortin. CRH is synthesized in the hypothalamus, and plays an important role in coordinating the endocrine, autonomic, and behavioral responses to stress and immune challenge. Studies in mice suggest that this receptor maybe involved in mediating cardiovascular homeostasis. Alternatively spliced transcript variants encoding different isoforms have been described for this gene.[provided by RefSeq, Jan 2011]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).